EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset

Zusammenhang zwischen Polypharmazie und Mortalität bei Patient:innen mit Herzinsuffizienz: Ergebnisse aus dem PULSE-Datensatz

Janine Beezer iD, Andrew L Clark iD, Adam Todd iD, Andrew Kingston iD, Andrew Husband iD

ESC Heart Failure · 2025-12-01 · 12 (6) · 4316-4325

DOI: 10.1002/ehf2.15445 ↗

Auf einen Blick

In einer retrospektiven Kohortenstudie mit 660 Patient:innen mit Herzinsuffizienz war Polypharmazie nach der Hospitalisierung mit Mortalität assoziiert, vor allem bei HFrEF. Nach strenger Anpassung blieb der Zusammenhang nicht in allen Analysen bestehen.

Fragestellung

Besteht bei Patient:innen mit Herzinsuffizienz ein Zusammenhang zwischen Polypharmazie und Mortalität nach Hospitalisierung?

Methode

Retrospektive longitudinale Beobachtungskohorte; Medikationsdaten bei Aufnahme und Entlassung der ersten Herzinsuffizienz-Hospitalisierung; Analyse mit Cox-Modellen und inverse probability weighting.

Ergebnisse

660 Patient:innen, mittleres Alter 76,1 Jahre, 56 % männlich; fast 60 % waren am Studienende verstorben. Bei HFrEF war Hyperpolypharmazie in der univariablen Analyse mit höherer Mortalität verbunden (HR 1,95; 95 %-KI 1,36–2,82).

Schlussfolgerung der Autor:innen

Alter, Geschlecht, CCI und CFS waren starke Mortalitätsprädiktoren. Nach gründlicher Confounder-Anpassung war Polypharmazie nach Hospitalisierung bei HFrEF mit Mortalität assoziiert, bei HFpEF nicht.

Kernaussagen

  • 660 Patient:innen mit Herzinsuffizienz, mediane Nachbeobachtung 2,9 Jahre
  • HFrEF: Hyperpolypharmazie mit höherer Mortalität assoziiert
  • HFpEF: kein Zusammenhang zwischen Hyperpolypharmazie und Mortalität

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Beobachtungsstudie in ESC Heart Failure, published online on 2025-10-11. Written by Janine Beezer and 4 co-authors. Institution: South Tyneside and Sunderland Foundation Trust, Sunderland Royal Hospital, Sunderland, UK. Major MEDLINE topics: Polypharmacy, Heart Failure, Stroke Volume. Cited 3 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY 4.0). Funded by: British Society for Heart Failure, Pharmacy Research UK.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Mortality remains high in heart failure despite advances in heart failure therapy. Heart failure patients are generally older, with multiple long-term conditions, and polypharmacy is common. This study explores the association between polypharmacy and mortality.

Methods

This retrospective longitudinal observational cohort study collected medication data on admission and discharge from the first heart failure hospitalisation. Association with mortality was explored using Cox proportional hazard models and inverse probability weighting regression analysis.

Results

A total of 660 patients were included, 367 (56%) male, mean age 76.1 (SD ±12.3) and almost 60% (338/660) had died at study end. Median follow-up time was 2.9 years (25th and 75th quartiles 1.6 and 4.5). It was rare to be discharged from hospital with no polypharmacy (5%, n = 31). Heart failure with preserved ejection fraction (HFpEF) was associated with a 32% (HR 1.32, CI 1.08–1.61, P = 0.007) higher mortality compared to HFrEF. In those with heart failure with reduced ejection fraction (HFrEF), univariable analysis showed hyperpolypharmacy was associated with twice the mortality compared to polypharmacy (HR 1.95, CI 1.36–2.82, P < 0.001). In multivariable analysis, the association between polypharmacy and mortality was lost. The average treatment effect for hyperpolypharmacy was associated with 26% (Coeff. −0.26, CI −0.43 to −0.09, P = 0.003) higher mortality than polypharmacy. The chance of survival to the end of follow-up was 80% (Coeff. 0.80, CI 0.64–0.95, P < 0.01) for those with polypharmacy, and 54% (Coeff. 0.54, CI 0.46–0.61, P < 0.01) for those with hyperpolypharmacy. In HFpEF, hyperpolypharmacy, univariable analysis was not associated with mortality (HR 0.93, CI 0.70–1.24, P = 0.63). Average treatment effect also showed that hyperpolypharmacy was not associated with mortality (Coeff. −0.03, CI −0.15 to 0.08, P = 0.55). The chance of survival to the end of follow-up was 67% (Coeff. 0.67, CI 0.58–0.77, P < 0.01) with polypharmacy and 64% (Coeff. 0.64, CI 0.57–0.71, P < 0.01) with hyperpolypharmacy.

Conclusions

Age, sex, CCI, and CFS are strong mortality predictors for HF irrespective of HF subgroup. Rigorous confounding adjustment suggests polypharmacy is associated with mortality following hospitalisation for HFrEF but not HFpEF. Further studies are needed to address the complex interplay between polypharmacy, age, comorbidity, and frailty.

Subjects

MeSH terms (MEDLINE)

PolypharmacyHeart FailureStroke VolumeHumansMaleFemaleAgedRetrospective StudiesFollow-Up StudiesAged, 80 and overSurvival RateLongitudinal StudiesRisk FactorsHospitalization

Author keywords

Heart failureMortalityOutcomesPolypharmacy

Authors and institutions

  • South Tyneside and Sunderland Foundation Trust, Sunderland Royal Hospital, Sunderland, UK.
  • School of Pharmacy, The Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, UK.
  • School of Pharmacy, The Faculty of Medical Sciences, Newcastle NIHR Patient Safety Collaboration (PSRC), Newcastle University, Newcastle upon Tyne, UK.
  • Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

ORCID profiles: Janine Beezer, Andrew L Clark, Adam Todd, Andrew Kingston, Andrew Husband

Funding

  • British Society for Heart Failure
  • Pharmacy Research UK

Cite

APA

Beezer, J., Clark, A. L., Todd, A., Kingston, A., & Husband, A. (2025). The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset. ESC Heart Failure, 12(6), 4316-4325. https://doi.org/10.1002/ehf2.15445

Vancouver

Beezer J, Clark AL, Todd A, Kingston A, Husband A. The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset. ESC Heart Failure. 2025;12(6):4316-4325. doi:10.1002/ehf2.15445

BibTeX
@article{Beezer2025,
  author = {Beezer, Janine and Clark, Andrew L and Todd, Adam and Kingston, Andrew and Husband, Andrew},
  title = {The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {6},
  pages = {4316--4325},
  doi = {10.1002/ehf2.15445}
}
Start for free →